66.17

0.56% -0.37

After Hours: 66.64 0.47 +0.71%

Bridgebio Pharma Inc (BBIO)

Overview News Price History Option Chain Financials Why BBIO Down? Discussions Forecast

Bridgebio Pharma Inc stock is traded at $66.17, with a volume of 1.78M. It is down -0.56% in the last 24 hours and up +3.83% over the past month. BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Previous Close:

$66.54

Open:

$65.71

24h Volume:

1.78M

Relative Volume:

0.67

Market Cap:

$12.83B

Revenue:

$353.78M

Net Income/Loss:

$-805.69M

P/E Ratio:

-15.80

EPS:

-4.1869

Net Cash Flow:

$-597.61M

1W Performance:

-2.13%

1M Performance:

+3.83%

6M Performance:

+23.96%

1Y Performance:

+89.22%

1-Day Range:

$64.71

$66.58

1-Week Range:

$62.77

$68.47

52-Week Range:

$28.32

$84.94

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Name

Bridgebio Pharma Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

(650) 391-9740

Address

3160 PORTER DR., PALO ALTO, CA

Employee

839

Twitter

Next Earnings Date

2026-02-24

Latest SEC Filings

BBIO's Discussions on Twitter

Compare BBIO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BBIO Bridgebio Pharma Inc	66.17	12.90B	353.78M	-805.69M	-597.61M	-4.1869
VRTX Vertex Pharmaceuticals Inc	460.82	121.40B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	764.93	83.25B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	728.11	46.39B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	320.51	43.41B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	292.94	33.09B	5.36B	287.73M	924.18M	2.5229

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Initiated	Barclays	Overweight
Jan-06-26	Initiated	Morgan Stanley	Overweight
Dec-11-25	Initiated	Bernstein	Outperform
Jul-30-25	Resumed	Raymond James	Outperform
Jul-21-25	Initiated	Truist	Buy
Jul-14-25	Initiated	Jefferies	Buy
Jul-09-25	Upgrade	Oppenheimer	Perform → Outperform
Jun-17-25	Initiated	Wolfe Research	Outperform
Mar-31-25	Initiated	Redburn Atlantic	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-03-24	Initiated	Oppenheimer	Perform
Sep-04-24	Initiated	Piper Sandler	Overweight
Mar-21-24	Resumed	Raymond James	Outperform
Jan-31-24	Initiated	BMO Capital Markets	Market Perform
Dec-08-23	Initiated	Wells Fargo	Overweight
Nov-07-23	Initiated	Citigroup	Buy
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Jul-18-23	Downgrade	Jefferies	Buy → Hold
Apr-19-23	Initiated	Evercore ISI	Outperform
Feb-06-23	Initiated	Cowen	Outperform
Dec-27-21	Reiterated	Mizuho	Buy
Dec-27-21	Reiterated	SVB Leerink	Outperform
Sep-10-21	Upgrade	BofA Securities	Neutral → Buy
May-21-21	Initiated	UBS	Buy
Mar-22-21	Reiterated	Goldman	Buy
Feb-22-21	Resumed	JP Morgan	Overweight
Feb-09-21	Resumed	Goldman	Buy
Jan-11-21	Reiterated	H.C. Wainwright	Buy
Dec-10-20	Reiterated	H.C. Wainwright	Buy
Jun-25-20	Initiated	BofA/Merrill	Neutral
May-19-20	Initiated	BTIG Research	Buy
Apr-13-20	Initiated	H.C. Wainwright	Buy
Feb-19-20	Initiated	Mizuho	Buy
Jul-26-19	Initiated	Raymond James	Outperform
Jul-22-19	Initiated	BMO Capital Markets	Outperform
Jul-22-19	Initiated	Goldman	Buy
Jul-22-19	Initiated	JP Morgan	Overweight
Jul-22-19	Initiated	Jefferies	Buy
Jul-22-19	Initiated	Piper Jaffray	Overweight
Jul-22-19	Initiated	SVB Leerink	Outperform

View All

Bridgebio Pharma Inc Stock (BBIO) Latest News

Mar 04, 2026

BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference - Bitget

Mar 04, 2026

BridgeBio Pharma to Present Phase 3 FORTIFY Trial Data on LGMD2I/R9 Therapy at 2026 MDA Conference - geneonline.com

Mar 04, 2026

BridgeBio to present LGMD2I/R9 trial data at MDA conference By Investing.com - Investing.com Australia

Mar 04, 2026

[144] BridgeBio Pharma, Inc. SEC Filing - Stock Titan

Mar 04, 2026

BridgeBio to present LGMD2I/R9 trial data at MDA conference - Investing.com Nigeria

Mar 04, 2026

TD Asset Management Inc Purchases Shares of 88,950 BridgeBio Pharma, Inc. $BBIO - MarketBeat

Mar 04, 2026